REJUVE THERAPEUTICS, INC. Trademark

Trademark Overview


On Thursday, November 9, 2023, a trademark application was filed for REJUVE THERAPEUTICS, INC. with the United States Patent and Trademark Office. The USPTO has given the REJUVE THERAPEUTICS, INC. trademark a serial number of 98263876. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, November 12, 2024. This trademark is owned by Rejuve Therapeutics, Inc.. The REJUVE THERAPEUTICS, INC. trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical and biological preparations for respiratory diseases and disorders; Pharmaceutical and biological preparations for use in pulmonology, immunology, oncology, infectious diseases, and degenerative diseases; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing COPD, chronic bronchitis, mucus hypersecretion, emphysema, asthma, sleep apnea, pulmonary hypertension, idiopathic pulmonary fibrosis (IPF), and other diseases, disorders, and conditions affecting the lungs and airways; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing cancer, fibrotic diseases, NASH, Crohn's Disease, osteoarthritis, viral infections, and hepatitis C; Pharmaceutical and biological preparations for improving air flow obstruction, reduce neutrophils and secreted elastase, improve mucociliary clearance, increase lung cell viability, increase alveolar regeneration, reduce smooth muscle proliferation, regulate cartilage dest...

Research and development in the fields of pharmaceuticals, biologics, and therapeutic treatments in the fields of pulmonology, immunology, oncology, infectious diseases, and degenerative diseases; Providing medical scientific research information in the fields of pharmaceuticals, biologics, and therapeutic treatments in the fields of pulmonology, immunology, oncology, infectious diseases, and degenerative diseases
rejuve therapeutics, inc.

General Information


Serial Number98263876
Word MarkREJUVE THERAPEUTICS, INC.
Filing DateThursday, November 9, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, November 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 17, 2024

Trademark Statements


Goods and ServicesPharmaceutical and biological preparations for respiratory diseases and disorders; Pharmaceutical and biological preparations for use in pulmonology, immunology, oncology, infectious diseases, and degenerative diseases; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing COPD, chronic bronchitis, mucus hypersecretion, emphysema, asthma, sleep apnea, pulmonary hypertension, idiopathic pulmonary fibrosis (IPF), and other diseases, disorders, and conditions affecting the lungs and airways; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing cancer, fibrotic diseases, NASH, Crohn's Disease, osteoarthritis, viral infections, and hepatitis C; Pharmaceutical and biological preparations for improving air flow obstruction, reduce neutrophils and secreted elastase, improve mucociliary clearance, increase lung cell viability, increase alveolar regeneration, reduce smooth muscle proliferation, regulate cartilage destruction, reduce inflammation; Therapeutic agents in the nature of nebulized peptides, monoclonal antibodies, and recombinant protein domains for reversing underlying mechanisms of COPD
NOT AVAILABLE"THERAPEUTICS, INC."
Goods and ServicesResearch and development in the fields of pharmaceuticals, biologics, and therapeutic treatments in the fields of pulmonology, immunology, oncology, infectious diseases, and degenerative diseases; Providing medical scientific research information in the fields of pharmaceuticals, biologics, and therapeutic treatments in the fields of pulmonology, immunology, oncology, infectious diseases, and degenerative diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, December 12, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, December 12, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameRejuve Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressHouston, TX 770028121

Party NameRejuve Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressHouston, TX 770028121

Trademark Events


Event DateEvent Description
Monday, November 13, 2023NEW APPLICATION ENTERED
Tuesday, December 12, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, June 18, 2024ASSIGNED TO EXAMINER
Tuesday, June 25, 2024NON-FINAL ACTION E-MAILED
Tuesday, June 25, 2024NON-FINAL ACTION WRITTEN
Tuesday, June 25, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, June 28, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, June 28, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 28, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 8, 2024FINAL REFUSAL E-MAILED
Thursday, August 8, 2024FINAL REFUSAL WRITTEN
Thursday, August 8, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, August 13, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, August 13, 2024EXAMINERS AMENDMENT -WRITTEN
Tuesday, August 13, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, August 13, 2024EXAMINER'S AMENDMENT ENTERED
Tuesday, August 13, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 13, 2024EXAMINERS AMENDMENT E-MAILED
Tuesday, August 13, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, August 14, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 28, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 17, 2024PUBLISHED FOR OPPOSITION
Tuesday, September 17, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 12, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT